Capacity, not interest
WCG's 2025 Clinical Research Site Challenges Report surveyed 611 research sites from July to September 2025. 45% said their challenges are restricting their capacity to take on new studies. Among U.S. sites the figure was 48%.
What sites ranked
Asked to name their top three challenges, sites put trial complexity first at 35%, followed by study start-up at 31% (budgets, contracts and builds), staffing at 30%, recruitment and retention at 28%, and long initiation timelines at 26%.
Where start-up slows
73% of sites named budgets and contracts as the leading contributor to start-up delays, and 76% of U.S. sites said the same. Each separate site agreement adds a budget and a contract to settle before that site can activate.
Where Hawthorne Health fits
One clinical trial agreement covers all our pharmacy-based community sites and our in-home visits, with one project manager across locations and centrally led feasibility and start-up oversight. On a Phase 3 vaccine program, our first site activated 14 days after contract signature, and the network enrolled 101 participants in five weeks of active enrollment.